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ABSTRACT
Sarcomas are uncommon malignancies
accounting for about 1% of all adult
malignancies. Sarcomas are a heterogeneous
group of tumors which includes more than
100 different subtypes. Surgery is the mainstay
therapy for localized disease. In selected
patients the combination of surgery with
radiotherapy achieves better local control and
offers the best chance of cure. Systemic
treatment including cytotoxic chemotherapy
or targeted therapies remains the mainstay
therapy for most patients with advanced
disease. There are a wide variety of clinical
situations, such that an individualized
treatment plan must be defined by a
multidisciplinary tumor board. Treatment
decisions should take into consideration the
histology, site of disease, stage, performance
status, treatment goals, and the patient’s
wishes. The management of patients should be
carried out in a center with expertise in the
treatment of sarcomas for optimal outcome.
This review will cover the different treatment
modalities of adult soft tissue sarcomas.
Keywords: Chemotherapy; Radiotherapy; Soft
tissue sarcoma; Surgery; Targeted therapy
INTRODUCTION
Soft tissue sarcomas (STSs) are mesenchymal
derived cancers which have more than 100
histological subtypes according to the most
recent World Health Organization
classification [1]. These tumors are rare and
account for less than 1% of all adult
malignancies [2]. In the USA 11,930 new cases
of STS are diagnosed each year with 4870 deaths
[3]. They arise from any part of the body, but
the majority occur in the extremities (59.5%)
followed by the trunk (17.9%) [4]. The most
common histologic subtypes in adults are
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sarcoma, and malignant peripheral nerve
sheath tumor (MPNST) [1]. Painless mass is the
most common clinical presentation. Tumor
tends to grow locally along tissue planes,
surrounded by a so-called pseudocapsule
which contains malignant cells infiltrating
adjacent tissues [1]; therefore, the dissection
along the pseudocapsule is contraindicated [5].
The presence of distant metastases at the time of
initial diagnosis is rare [6]. The most common
pattern of spread is via blood, typically to the
lung [6]. Lymph node metastases are infrequent
(less than 3%) [7], with the exception of certain
histologies such as epithelioid sarcoma,
rhabdomyosarcoma, angiosarcoma, and clear
cell sarcoma [7]. Pretreatment evaluation
includes magnetic resonance imaging of the
primary site and chest computed tomography
[5]. Tumor stage is the most important
prognostic factor. The most recent, 7th edition
of the American Joint Committee on Cancer
(AJCC) system is the most widely used. It
incorporates tumor size, depth, lymph node
involvement, distant metastases, and histologic
grade in determining four stage groups with
different outcome [8]. Thus, reported 5-year
overall survival (OS) rates for stages I, II, and III
were 90%, 81%, and 56%, respectively [8]. In
addition to tumor stage, other prognostic
factors are anatomic site, histologic subtype,
age, and surgical margins [9]. The management
of patients with STS requires a multimodality
treatment provided by an expert
multidisciplinary team working in a reference
center or within a reference network [5].
Thereby, clinical practice guidelines
recommend referral of all patients with
suspected sarcoma to a reference center for
appropriate diagnostic and optimal outcome
[5]. In fact, Gustafson et al. [10] demonstrated
that patients treated at a tumor center have
better outcome as compared to patients who
were not referred to a tumor center or those
who were referred to a tumor center after
surgery. In their series local recurrence was 2.4
times higher when patients were treated outside
of a reference center and 1.3 times higher if the
patients were referred to a tumor center after
surgery [10].
The present review covers different treatment
modalities for adult STSs based on recent clinical
practice guidelines, data from clinical trials, and
meta-analysis. We have excluded from this
review extraskeletal Ewing sarcoma, embryonal
rhabdomyosarcoma, alveolar rhabdomyosar-
coma, and gastrointestinal stromal tumors
(GIST), as they belong to separate therapeutic
approaches. This article is based on previously
conducted studies and does not involve any new
studies of human or animal subjects performed




Surgery is the standard treatment of localized
STS [5] and consists of a wide surgical resection,
with total en bloc excision of the primary
tumor, the biopsy site, and a rim of normal
tissues around the tumor [11]. Dissection along
the pseudocapsule is strictly prohibited [5].
Resection margins represent the main risk
factor for local recurrence [11]. The Union for
International Cancer Control (UICC)
recommends to report the quality of surgery in
STS according to the resection type (R) with R0
as in sano, R1 as microscopic residual disease,
and R2 as macroscopic residual disease.
Resection type should be assessed collegially
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by pathologists and surgeons for an accurate
estimation of resection margins, since the
decision for re-excision or complementary
treatment depends on the determination of
the quality of surgery [12, 13]. There is no
consensus regarding the relevant cutoff of the
minimal margin [5]. In general, 1-cm margins
are recommended; however, close margins may
be necessary in some cases to preserve
uninvolved major neurovascular structures
[13]. Moreover, narrow margins of resistant
anatomical barriers, such as muscular fasciae,
periosteum, and epineurium, are likely to be
adequate [5].
As regards sarcomas of the extremities, it has
been demonstrated that limb-sparing surgery
alone or in combination with radiotherapy (RT)
in selected patients offers comparable rates of
disease control and survival as amputation, as
long as wide resection margins are achieved
[14–16]. Therefore, primary limb amputation
must be avoided in most patients. However,
amputation may be the only potentially
curative option in some cases including large
and extensive tumors which compromise the
achievement of a conservative approach with a
good functional limb outcome or in case of
major complications [17]. Those situations
should be carefully assessed by a
multidisciplinary team before carrying out
amputation.
Because lymph node involvement is
uncommon in STS, systematic regional node
dissection is not recommended [5]. Node
dissection should be performed only if there is
evidence of lymph node disease [7]. In this
setting, it has been reported that radical
lymphadenectomy for isolated regional lymph
node metastases provides long-term survival:
46% 5-year survival, with a median survival of
16.3 months versus 4.3 months in patients not
treated with lymph node dissection [7].
However, it is unclear if treatment of occult
node metastases based on earlier detection of
metastatic nodes by sentinel lymph node
biopsy or positron emission tomography
would improve outcome in histologies with
higher frequency of lymph nodes metastasis
including epithelioid sarcoma,
rhabdomyosarcoma, angiosarcoma, synovial
sarcoma, and clear cell sarcoma [18, 19].
Surgery alone with negative margins
provides a local control rate close to 93% in a
selected subset of patients (superficial and low
grade tumors that are 5 cm or less in size, and
selected truly intracompartmental tumor) [20,
21]. However, some patients are at high risk of
recurrence and will require complementary
treatment [22].
Radiotherapy
The benefit of RT as adjuvant treatment to
limb-sparing surgery has been initially
addressed in comparison with radical surgery.
These studies have shown that RT, when
combined with conservative surgery, provides
similar rates of local control to those achieved
with amputation [14]. Since the publication of
these results, amputation as a primary therapy
has largely been abandoned for most patients
[15]. So, with the emergence of RT in the
management of STSs, two randomized trials
using different modalities of radiation therapy
(external beam RT (EBRT) [23] or brachytherapy
[24]) have been conducted in order to assess the
impact of adjuvant RT on local and systemic
recurrence in patients with localized STS
(Table 1). The two studies demonstrated that
adding RT to limb-sparing surgery reduces the
risk of local recurrence by 20–25% when
compared to limb-sparing surgery alone
without any advantage in OS [23, 24]. The
benefit of RT was seen in high-grade and
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low-grade tumors in one trial [23], whereas it
was limited to high-grade tumors in the other
one [24]. The identification of patients who
require adjuvant RT is mandatory. Several
predictor factors of local recurrence have been
identified. The most important factor is surgical
margins [25]. Patients with positive margins are
at increased risk of local recurrence. A relative
risk (RR) of 2.9 [95% confidence interval (CI)
1.8–4.6] has been reported in patients with
positive margins who did not receive adjuvant
treatment [26]. Positive surgical margins have
been associated with local recurrence risk even
in patients treated with combined surgery and
RT [9]. Re-excision seems to be the best option
for favorable outcome in patients with marginal
resection. Zagars et al. [27] reported local
control rates of 85%, 85%, and 82% at 5, 10,
and 15 years, respectively, for patients who
underwent re-resection versus 78%, 73%, and
73%, respectively, for patients who did not
undergo re-resection [27]. Therefore, re-excision
must be strongly considered in case of R2 or R1
resections, if adequate margins can be achieved
without major morbidity [5, 13].
Postoperative RT improves local control in
patients with marginal excisions and in those
with residual tumor cells after re-excision. The
10-year local recurrence rates for patients
treated with surgery alone and patients treated
with combined surgery and RT was 17% (95%
CI 8–32%) versus 53% (95% CI 25–75%),
respectively (P = 0.005), in patients with
marginal resection and 84% in the RT group
versus 37% in the no-RT group (P = 0.001) in
patients with residual cells after re-excision [28].
Several independent adverse prognostic
factors for local recurrence have been reported
Table 1 Randomized trials of radiotherapy in localized adult soft tissue sarcomas
Study N Treatment Local recurrence DFS (5 years) OS (5 years)
Rosenberg et al. [14] 43 LSS ? postoperative RT 14.8% 71% 83%
Amputation 0% 78% 88%
P = 0.06 P = 0.75 P = 0.99
Yang et al. [23] 141 LSS ? postoperative RT 0.01% NR 75%b
LSS 23.9% NR 74%b
P = 0.0001 P = 0.71
Pisters et al. [24] 119 Surgery ? brachytherapy 16.7% 83%a 84%c
Surgery 29% 76%a 81%c
P = 0.04 P = 0.60 P = 0.65
O’Sullivan et al. [31] 190 Preoperative RT (50 Gy) 7% 58% 73%
Postoperative RT (66 Gy) 8% 59% 67%
P = 0.48 P = 0.48 P = 0.48
DFS disease-free survival, LSS limb-sparing surgery, NR not reported, OS overall survival, RT radiotherapy
a 5-year distant metastasis-free survival
b 10-year overall survival in high-grade STS
c 5-year disease-speciﬁc survival
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in retrospective series and population-based
registries [8, 9, 25, 29]. The most relevant are
recurrent disease at presentation, histology, age,
tumor grade, deep location, and tumor size.
A prospective nomogram which aims to
estimate the risk of local recurrence for an
individual patient has been established
recently. The nomogram was developed from a
prospective sarcoma database including 684
patients with primary, non-metastatic,
extremity STS treated with limb-sparing
surgery alone without adjuvant therapy. It
includes five independent predictor factors of
relapse: age, size, surgical margin, grade, and
histology. The nomogram is useful to quantify
individual 3- and 5-year risk of local recurrence;
however, there is insufficient evidence to
support routine use of this nomogram for
clinical decision-making [22].
The recent clinical practice guidelines
recommend radiation therapy as the standard
treatment of lesions that are high grade, deep,
and larger than 5 cm [5, 13]. There is no
consensus regarding the indication of adjuvant
RT for selected cases, namely STSs that are low
or high grade, superficial, and larger than 5 cm;
low grade, deep, and smaller than 5 cm; or low
grade, deep, and larger than 5 cm. So the
decision should be discussed in a
multidisciplinary setting and must be shared
with the patient [5]. Most high-grade lesions
that are deep and smaller than 5 cm should be
treated with surgery followed by radiation
therapy with exceptions to be discussed in a
multidisciplinary board [5, 13].
RT can be administered preoperatively or
postoperatively [5]. A phase III trial comparing
these two modalities reported similar efficacy in
terms of local control and survival [30]. After a
median follow-up of 6.9 years, over 90% of
patients are controlled locally, with similar rates
of progression-free survival (PFS) and OS [31].
However, the two approaches differ
substantially in their side effects. Acute wound
complications were significantly more common
with preoperative RT (35%) as compared to
postoperative RT (17%; 95% CI 5–30%;
P = 0.01). Wound healing was affected by the
extent of the surgery and anatomical site of the
tumor [30]. Postoperative RT induces higher
rates of late complications including edema,
fibrosis, and joint stiffness, which are often
irreversible and adversely affect functional
outcome [30]. The differences in the morbidity
and functional outcome between these two
approaches could be related not only to the
timing of RT but also to the larger radiation field
and the higher doses (66 versus 50 Gy)
associated with postoperative RT [30].
The optimal timing of radiation therapy has
yet to be defined. However, because of the lower
rates of long-term complications and the better
functional outcome reported in O’Sullivan
et al.’s [30] trial there is a current trend toward
preoperative RT, especially when the dose and
field size are important issues. Nevertheless,
postoperative RT might be preferable if severe
wound-healing complications are anticipated.
Modern RT techniques such as image-guided
RT and intensity-modulated RT treatment
might reduce the risk of acute wound-healing
problems when preoperative RT is administered
and the risk of long-term side effects when
postoperative RT is given [32].
The treatment should be individualized and
the best option should be discussed in a
multidisciplinary tumor board. A total dose of
50 Gy in 1.8- to 2-Gy fractions is recommended,
possibly with a boost up to 66 Gy, depending on
presentation and resection margins [5].
Brachytherapy is another modality of RT in
which a radiation source is placed inside the
targeted area. It delivers high dose of radiation
to the tumor while minimizing the dose to
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surrounding normal tissues [21]. Postoperative
brachytherapy (45 Gy) reduces recurrence in
high-grade STSs by 23% [21]. There is no
randomized trial comparing brachytherapy to
EBRT. Further studies are needed to identify
patients for whom brachytherapy may be
preferred.
Chemotherapy
In spite of effective local treatment, 25% of
patients will develop distant metastases [9, 33].
Thus an effective systemic treatment to
eradicate micro-metastases is strongly
warranted. Over 20 randomized trials and two
meta-analyses have investigated the role of
adjuvant chemotherapy in localized adult STS
(Table 2). Study results were conflicting. Thus,
the role of adjuvant chemotherapy in patients
undergoing local therapy remains unclear. The
first meta-analysis by the Sarcoma Meta-analysis
Collaboration published in 1997 found an
improvement in local and distant
recurrence-free intervals in the chemotherapy
group, but no benefit in terms of OS [34].
However in the subset of patients with sarcomas
of the extremities there was a statistically
significant benefit in terms of OS in favor of
adjuvant chemotherapy [hazard ratio (HR) for
death = 0.80; P = 0.029] [34]. This
meta-analysis includes early randomized trials
which used suboptimal adjuvant regimens. An
updated meta-analysis including four
additional new trials which used optimal
dosages of doxorubicin in addition to
ifosfamide confirms the limited benefit of
adjuvant chemotherapy in terms of local
recurrence, distant recurrence, and overall
recurrence [35]. However, in contrast to the
earlier meta-analysis, adjuvant chemotherapy
yielded improvement in OS with an HR of 0.77
(95% CI 0.64–0.93; P = 0.01). The benefit is
further improved with regimens combining
ifosfamide with doxorubicin with an absolute
risk reduction of 11% (95% CI 3–19%; P = 0.01)
or a 30% versus 41% risk of death [35].
However, a survival benefit could not be found
in the most recent and largest study of the
European Organization for Research and
Treatment of Cancer (EORTC) which was not
included in the updated meta-analysis [36]. The
trial randomly assigned 351 patients to receive
either adjuvant chemotherapy (doxorubicin at
75 mg/m2 with ifosfamide at 5 g/m2) or no
additional systemic chemotherapy following
surgery. The lack of efficacy might be
influenced by the inclusion of patients with
non-extremity sarcomas (33%), low- and
intermediate-grade tumors (55%), and of
tumors smaller than 10 cm (63%), as well as
by the low dose of ifosfamide. Therefore, no
definitive conclusions can be drawn. A pooled
analysis combining individual patient data
from this trial with another large randomized
adjuvant trial found no survival benefit of
adjuvant chemotherapy except in patients
with marginal resection (Table 2) [37].
It is unknown whether adjuvant
chemotherapy may be particularly beneficial
in specific chemosensitive histologies such as
myxoid, round cell liposarcoma [38] and
synovial sarcoma [39]. Available data from
retrospective series suggest a potential benefit
of adjuvant chemotherapy in selected
histologies [40, 41]; however, neither
randomized clinical trials nor meta-analyses
have confirmed this finding [34, 35, 37].
On the basis of these data, adjuvant
chemotherapy is not standard treatment in
adult-type STS. It can be proposed as an
option in high-risk individual patients (with a
high-grade, deep tumor larger than 5 cm), but
should not be considered in histological
subtypes known to be chemoresistant [5].
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A new therapeutic approach consisting of
regional hyperthermia in addition to systemic
chemotherapy has been investigated in a large
randomized phase III trial [42]. Patients with
localized high-risk STS (G2–3, deep, at least
5 cm) were randomly assigned to receive either
neoadjuvant chemotherapy alone or combined
with regional hyperthermia in addition to local
therapy. This approach was associated with a
local PFS advantage (HR = 0.58; 95% CI
0.41–0.83) and disease-free survival benefit
(HR = 0.70; 95% CI 0.54–0.92]). Response rate
was higher in the group with regional
hyperthermia 28.8% versus 12.7% in the
group that received chemotherapy alone
(P = 0.002). OS was better in the combined
therapy group with an HR = 0.66 (95% CI
0.45–0.98; P = 0.038) [43]. Thus, this
therapeutic strategy offers a new therapeutic
option for patients with high-risk STS including




For patients with unresectable primary locally
advanced tumors, combined therapeutic
modalities should be considered. The main
objective of combined therapeutic modalities
is to ovoid mutilating surgery, to improve local
control, OS, and minimize sequelae.
Isolated limb perfusion (ILP) is the most
investigated approach in this setting. This
technique provides high concentration of
antineoplastic agents locally without exposing
the patient to high systemic levels of the drug
by isolating the vasculature of a limb
temporarily. ILP uses high doses of tumor
necrosis factor alpha (TNFa) and melphalan
with or without interferon and is usually
associated with local hyperthermia. Several
groups have reported their experience with
upfront ILP. Results were consistent among all
these studies. The overall response rate was
greater than 70% and limb salvage rate about
80% [44–48].
Regional hyperthermia in addition to
systemic chemotherapy might be a good
alternative. A phase II trial which was
conducted in locally advanced primary or
recurrent STS found an overall response rate of
17% with a high rate of histological response
and a better outcome in patients responding to
the combined approach [49]. Furthermore, a
subgroup analysis of the most recent phase III
trial found better local PFS in patients with very
large tumors (larger than 12 cm) in the
chemotherapy plus regional hyperthermia
group as compared with patients receiving
chemotherapy alone [43].
Note that both regional hyperthermia and
ILP are not widely available because of the
highly technical procedures required for these
approaches.
Preoperative chemoradiotherapy represents
another option to manage locally advanced STS
[5] and available data suggest that it can be
administered safely [50]. Concomitant
chemoradiotherapy with low dose doxorubicin
provided 67% objective response (11%
complete and 56% partial response) in 115
patients. Thirty-nine responders underwent
surgery including 24 primary tumors and 15
relapses. The median survival was 29 and
50 months in responder patients [51]. Limited
data exist regarding the concomitant use of
ifosfamide with RT. A retrospective series of 43
patients has reported promising results that
need to be confirmed by further studies [52].
Concurrent multi-agent chemotherapy
(doxorubicin, ifosfamide, and dacarbazine)
with RT was assessed in the Radiation Therapy
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Oncology Group (RTOG) study involving 66
patients. The 5-year rates of distant and
locoregional failure (including amputation)
were 28% and 22%, respectively. Five-year OS
was 71%. But serious treatment-related
toxicities were experienced in 83% of cases;
11% had major postoperative complications,
and three patients experienced fatal grade 5
toxicities [53].
The benefit of neoadjuvant chemotherapy
alone in the management of locally advanced
STS is uncertain. In fact, it is unknown if
upfront systemic chemotherapy may convert
an initially unresectable tumor to a resectable
one or if it may improve the rate of
margin-negative resection. The single phase II
trial assessing the impact of preoperative
systemic chemotherapy in high-risk STS
(tumors of at least 8 cm, high grade, locally
recurrent, inadequate surgery) failed to show
any benefit [54]. This option could be
considered in chemosensitive STS using
multi-agent chemotherapy with anthracycline,
ifosfamide with or without dacarbazine given to
the higher response rate achieved by these
protocols [55, 56].
In the absence of randomized controlled
trials to define the most effective strategy to
manage locally advanced STS, there is no
consensus among reference centers and
therapeutic options are usually influenced by
the availability of technical equipment and the
institutional experience.
LOCALLY RECURRENT SOFT TISSUE
SARCOMAS
About 15% of patients with STS will develop a
local relapse in spite of effective local therapy
for the primary lesion [57, 58]. Local recurrence
occurs mostly within the first 2 years [57]. The
outcome is poorer as compared to primary cases
because of the increased risk of distant failure
[59]. Wide surgical resection is the cornerstone
of treatment [5]. Radiation therapy improves
local control and should be considered [5, 13].
However, achieving adequate surgical margins,
salvage of the limb, and re-irradiation are often
an issue in patients with recurrent STS.
Functional conservative management is
always preferable but not always possible. In
some cases, amputation remains the only
potentially curative option, especially in
previously irradiated patients.
In patients who had prior RT for their
primary tumor, Indelicato et al. [60]. reported
high morbidity with re-irradiation with 50% of
serious complications requiring either
reoperation or leading to permanent
functional impairment. Brachytherapy can be
an alternative for patients who had prior RT,
since it provides superior rates of local control
with acceptable complications [61].
Other options including neoadjuvant
systemic chemotherapy or regional
chemotherapy can be discussed. In fact,
promising results have been reported with ILP
in the management of recurrent disease. A
report of 26 patients with recurrent STS, in the
irradiated field, treated with TNFa-based ILP has
shown a response rate of 70%. Amputation was
avoided in 17 patients (65%). Local recurrence
rate was 45% in patients with multiple tumors
and 27% in patients with a single tumor [62].
Regional hyperthermia combined with systemic
chemotherapy might also be a good option in
patients with recurrent STS. A subgroup analysis
demonstrated that this new intervention results
in significantly better local PFS compared with
systemic neoadjuvant chemotherapy alone [43].
Further trials are needed to assess the potential
benefit and the safety profile of this new
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treatment in this specific population of
patients.
TREATMENT OF METASTATIC SOFT
TISSUE SARCOMAS
Management of metastatic STS is a challenging
problem. Treatment is essentially palliative and
the potential for cure decreases drastically. The
reported median OS is about 12–18 months [63,
64]. However, about 5–8% of patients are alive
progression-free 5 years after the initial
diagnosis of metastasis, and most will not
relapse later [65]. Chemotherapy is the
mainstay of treatment in the metastatic
setting. However, surgery of metastatic lesions
if feasible should be offered since it provides
long-term survival [66]. Reported median
survival after complete excision of isolated
lung metastases is 33–35 months versus
11–13 months in patients with non-surgical
treatment [66, 67]. Patients with
extrapulmonary metastases can also achieve
significant long-term survival when a complete
resection is possible for both the pulmonary
and extrapulmonary metastases [66].
Unfortunately most patients are not
amenable to ablative approaches. In these
instances, treatment is palliative and is based
on systemic chemotherapy.
Chemotherapy
Doxorubicin alone at the dose of 75 mg/m2
once every 3 weeks is considered the treatment
of choice in the first-line setting. It achieves a
response rate of 10–25% and a median survival
in the range of 1 year [63, 64]. It is the most
effective chemotherapeutic agent available
against multiple histological subtypes [68]. The
maximum cumulative dose that should be
administered should not extend 550 mg/m2 to
avoid cumulative cardiotoxicity. Pegylated
liposomal doxorubicin has similar efficacy
with an improved toxicity profile as compared
to doxorubicin in a phase II trial. However
response rates were lower than normally
expected (ca. 10%), probably because of the
high proportion of GIST in this study
population [69].
The second most commonly used drug in
soft tissue sarcoma is ifosfamide. Used as
monotherapy, ifosfamide results in response
rates of 20–25% in non-pretreated patients
[70–72]. Ifosfamide has higher activity in
synovial sarcoma and less antitumor activity
in leiomyosarcoma [73]. The response rate to
ifosfamide is both dose- and
schedule-dependent [72]. A randomized
phase II study comparing standard-dose
ifosfamide 5 g/m2 over 24 h versus ifosfamide
3 g/m2 daily for 3 days reported a response rate
of 10% for the lower-dose treatment and 25%
for the higher dose [71]. Therefore, the most
commonly used scheme is 3 g/m2 ifosfamide
administered on days 1, 2, and 3, repeated every
3 weeks. A role for high-dose ifosfamide
(14–18 mg/m2) has been suggested in the
treatment of metastatic synovial sarcoma [74].
A head-to-head comparison of doxorubicin
and ifosfamide in first-line treatment for
patients with advanced and/or metastatic soft
tissue sarcoma found no differences in PFS, OS,
or response rates. However, grade 4 toxicities
were more frequent in the ifosfamide arms [75].
This finding supports the use of single-agent
doxorubicin as the treatment of choice in
metastatic STS, though ifosfamide is a
reasonable alternative if patients cannot be
treated with an anthracycline initially.
Multi-agent chemotherapy with doxorubicin
plus ifosfamide in first-line treatment of
metastatic STS results in higher overall
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response rate (26.5% versus 13.6%), but without
survival advantage over single agent
doxorubicin [64]. Therefore, combination
therapy may be considered only when a tumor
response is felt to be potentially advantageous
[5].
Ifosfamide may be used after failure of
anthracycline-based chemotherapy in patients
who did not progress on it previously [5, 13].
The median survival of patients exposed to
ifosfamide in second-line treatment after
doxorubicin failure is in the range of
35–45 weeks with a median
time-to-progression of 6–14 weeks [70, 71]. For
patients who have already received
standard-dose ifosfamide, high-dose ifosfamide
is a reasonable option [76, 77].
Other conventional cytotoxic drugs such as
dacarbazine [78, 79], temozolomide [80],
pacliatxel [81], docetaxel [82–84], gemcitabine
[82, 83], and carboplatin [85] have
demonstrated modest antitumor activity in
pretreated patients with advanced STS
(response rate less than 20%) but yield disease
stabilization. Some of these agents have shown
the highest antitumor activity in selected
histological subtypes such as taxane in
angiosarcomas [81, 86], gemcitabine in
leiomyosarcoma and angiosarcoma [87–89],
dacarbazine in leiomyosarcoma and solitary
fibrous tumor [5], and eribulin in liposarcoma
and leiomyosarcoma [90]. Thus a personalized
treatment based on a histology-driven approach
may improve results and patients outcome.
Eribulin has been shown to improve OS by
2 months (13.5 versus 11.5 months) as
compared with standard treatment
dacarbazine in heavily pretreated patients with
advanced liposarcomas or leimyosarcomas. A
total of 452 patients have been enrolled in a
randomized open label multicenter phase III
trial (Study 309). The study’s primary end
point of OS was met. Eribulin reduced the risk
of death by 23% (HR = 0.768; 95% CI
0.618–0.954; P = 0.017). However, secondary
end points (PFS) were not significantly
different (median PFS was 2.6 months in both
arms). The 2 months improvement seen with
eribulin must be weighed against the higher
rates of adverse events in the eribulin group;
neutropenia (44% versus 24%), peripheral
sensory neuropathy (20% versus 4%), pyrexia
(28% versus 14%), and alopecia (35% versus
3%), with higher rates of grade 3 (63% versus
53%), grade 4 (26% versus 20%), and toxic
death (4% versus 1%) [91].
Trabectedin is a new agent that acts by
binding to the minor groove of the DNA
double strand and blocks the cell cycle in late
S and G phases. Trabectedin results in a low
response rate (8%) but yields prolonged disease
stabilization. Leiomyosarcoma and myxoid
liposarcoma appear to be more sensitive to
trabectedin. A particularly higher activity was
described in myxoid liposarcoma [92, 93]. It is
approved for advanced previously treated STS in
Europe on the basis a randomized phase II trial
[93]. A recent phase III trial comparing
trabectedin with dacarbazine in patients with
liposarcoma and leiomyosarcoma confirms the
results from the prior phase II study. The trial
was conducted in 518 patients who previously
received an anthracycline-containing regimen
followed by at least one additional line of
chemotherapy. The primary end point was OS.
Secondary outcome measures included PFS,
objective response rate, and safety. There was a
highly statistically significant difference in PFS
(4.2 months with trabectedin versus 1.5 months
with dacarbazine HR = 0.55; P\0.0001).
However, this trial found no improvement in
OS (median OS was 12.4 months with
trabectedin versus 12.9 months with
dacarbazine (HR = 0.87; 95% CI 0.644–1.181;
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P = 0.374). The safety profiles were consistent
with the well-characterized toxicities of both
drugs [94].
Several other multi-agent combinations of
active drugs in STS have been investigated.
Doxorubicin plus dacarbazine leads to a
response rate of 30% without a benefit in
terms of OS [95, 96]. This regimen is a
reasonable choice in the first-line treatment of
leiomyosarcoma which is less sensitive to
ifosfamide [5], or in patients in whom
ifosfamide is contraindicated.
The combination of gemcitabine plus
docetaxel is widely used in second-line
treatment especially in leiomyosarcoma and
undifferentiated pleomorphic sarcoma. The
most relevant trial in this field has compared
gemcitabine with and without docetaxel in
patients with advanced STSs. This phase II
randomized trial showed the combination to
be superior to single-agent gemcitabine in terms
of response rate, but also in terms of PFS and OS,
but with increased toxicity [83].
The combination of gemcitabine and
docetaxel shows no advantage over standard
of care doxorubicin as first-line treatment of
advanced STS. A recent prospective randomized
controlled phase III trial compared this
combination with single-agent doxorubicin as
first-line treatment in advanced unresectable or
metastatic STS. A total of 257 patients were
enrolled. The primary end point was PFS rate
(PFR) at 24 weeks. In the doxorubicin group
46.1% of patients were progression-free at
24 weeks versus 46% in the gemcitabine plus
docetaxel group. The HR indicated superiority
of doxorubicin (HR = 1.28; 95% CI 0.98–1.67;
P = 0.07). Median OS was 71 weeks versus
63 weeks (HR = 1.07; 95% CI 0.77–1.49) for
doxorubicin versus gemcitabine plus
docetaxel, respectively. Thus, doxorubicin
remains the standard first-line treatment for
locally advanced/metastatic STS [97].
The combination of dacarbazine and
gemcitabine was shown to improve the OS
(16.8 versus 8.2 months) and PFS (4.2 versus
2 months) over dacarbazine in 113 patients
with previously pretreated STS [98].
TARGETED THERAPIES
Pazopanib is an oral kinase inhibitor targeting
VEGF-R, PDGFR, and c-KIT. It is the first and the
only antiangiogenic drug approved for the
treatment of refractory non-adipocytic soft
tissue sarcoma [99]. After promising results in
a phase II trial [100], a large randomized
phase III trial (PALETTE) was conducted. The
PALETTE trial showed a benefit in terms of PFS
averaging 3 months (median 4.6 versus
1.6 months; P\0.0001) for pazopanib given
up to progression in refractory non-adipocytic
soft tissue sarcoma patients [101]. However, no
significant benefit in terms of OS was found; the
median OS in patients treated with pazopanib
was 12.5 versus 10.7 months in the placebo arm
(P = 0.25). This was explained by the use of
post-trial systemic therapy with other agents in
the placebo group. The objective response rate
was 6% for pazopanib versus 0% for placebo,
with 67% stable diseases in the pazopanib arm
versus 38% in the placebo arm [101]. In the
PALETTE trial, adipogenic tumors were
excluded on the basis of the lack of activity of
pazopanib in this histology subtype in the
phase II trial. However, an ongoing trial
(ClinicalTrials identifier NCT1506596) will
assess pazopanib’s activity in adipocytic
sarcomas including dedifferentiated,
myxoid-round cell, pleomorphic, and mixed
type [102], since these genetic subtypes have
vascular patterns and may theoretically respond
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to pazopanib [102]. The most common adverse
events of pazopanib were fatigue, diarrheas,
nausea, weight loss, and hypertension [101].
Retrospective analysis on pooled data from the
previously cited phase II and III EORTC trials
showed that good performance status, low/
intermediate grade of the primary tumor, and
a normal hemoglobin level at baseline were
advantageous for long-term outcome.
Long-term responders were defined as patients
with PFS of at least 6 months (36%), long-term
survivors as patients who survived for at least
18 months (34%) [103].
There is some evidence of the activity of
several molecular targeted agents, including
tyrosine kinase inhibitors and mammalian
target of rapamycin (mTOR) inhibitors in
selected histologies. However, these agents are
not approved by regulatory authorities for the
treatment of STS and should be preferably used
within clinical trials [13].
Cediranib, a potent inhibitor of VEGFR
receptors, has shown activity in alveolar soft
part sarcoma (ASPS) with a disease control rate
at 24 weeks of 84% in a phase II trial [104].
Sunitinib, an oral angiogenesis inhibitor,
achieved promising results in patients with
solitary fibrous tumors (n = 10) with 70%
objective response and response duration of
more than 6 months in five cases [105].
Sunitinib has also shown clinical efficacy in
five of nine patients with ASPS treated with
sunitinib 37.5 mg daily, continuously [106].
Crizotinib, an orally ATP-competitive
inhibitor of the ALK and MET tyrosine kinases,
has shown antitumor activity in
ALK-rearranged inflammatory myofibroblastic
tumor [107].
Regorafenib, a multikinase inhibitor,
demonstrated promising activity and an
acceptable toxicity profile in a recent
randomized placebo-controlled phase II study
(REGOSARC). The trial included 110 patients
with metastatic STS. The patients were
previously treated with doxorubicine,
ifosfamide, trabectedin, or pazopanib (median
of prior lines 2, range 1–3). The median PFS of
leimyosarcoma patients was 4 months with
regorafenib versus 1.9 months with the
placebo (HR = 0.49; 95% CI 0.27–0.89;
P = 0.017) and 4.6 months versus 1.0 month
with regorafenib and placebo, respectively
(HR = 0.38; 95% CI 0.20–0.74; P = 0.002) in
other types of STS [108].
Ridaforolimus, an mTOR inhibitor, has been
tested in a phase II trial conducted in 213
patients with advanced STS. Out of 193
patients with an evaluable response, 28%
showed clinical benefit. These encouraging
results led to a phase III trial (SUCCEED)
which investigated maintenance therapy with
ridaforolimus after chemotherapy in patients
with metastatic STS. The PFS was improved with
52% gain in median PFS (22.4 weeks for
ridaforolimus versus 14.7 weeks for placebo;
HR = 0.72; P\0.001). However, this trial failed
to show a benefit in OS.
Sirolimus, another mTOR inhibitor, has
resulted in significant clinical activity in
patients with malignant perivascular
epithelioid cell tumors (PEComa) through a
mechanism involving the mTOR1 pathway,
pathologically activated by loss of TSC1/TSC2
tumor suppressor complex in PEComa [109].
More recently, olaratumab, a human
anti-platelet-derived growth factor alpha
(PDGFa) monoclonal antibody has shown
promising results in the treatment of advanced
STS. It is the first agent added to doxorubine to
achieve an improvement in OS (HR = 0.44;
P = 0.0005) in a randomized phase II trial [110].
Despite a significant number of phase II trials
of targeted therapies, a limited number of
agents are tested in phase III trials.
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Determining the optimal trial design and
identifying the predictive biomarkers are
crucial steps for the development of these drugs.
CONCLUSIONS
The management of adult STS is complex and
should be carried out in a center with expertise
in the treatment of sarcomas. A
multidisciplinary approach is required for
optimal outcome. Clinical guidelines still face
some uncertainty given the heterogeneity of the
available data. New methods for clinical trials
are needed to generate reliable evidence for
standard practice.
ACKNOWLEDGMENTS
No funding or sponsorship was received for
publication of this article. All named authors
meet the International Committee of Medical
Journal Editors (ICMJE) criteria for authorship
for this manuscript, take responsibility for the
integrity of the work as a whole, and have given
final approval for the version to be published.
Disclosures. Samia Arifi, Rhizlan Belbaraka,
Rabie Rahhali, and Nabil Ismaili have nothing
to disclose.
Compliance with ethical standards. This
article is based on previously conducted
studies and does not involve any new studies
of human or animal subjects performed by any
of the authors.
Open Access. This article is distributed under
the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit to
the original author(s) and the source, provide a
link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Fletcher CDM, Bridge JA, Hogendoorn PCW,
Lyon MF. World Health Organization
classification of tumours of soft tissue and bone.
4th ed. Lyon: IARC Press; 2013.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer
statistics. CA Cancer J Clin S. 2004;54:8–29.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics.
CA Cancer J Clin. 2015;65(1):5–29.
4. Lawrence W Jr, Donegan WL, Ntarajan N, Mettlin
C, Beart R, Winchester D. Adult soft tissue
sarcomas. A pattern of care survey of the
American College of Surgeons. Ann Surg.
1987;205(4):349–59.
5. The ESMO/European Sarcoma Network Working
Group. Soft tissue and visceral sarcomas: ESMO
Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 2014;25
Suppl 3:iii102–iii112.
6. Christie-Large M, James SL, Tiessen L, Davies AM,
Grimer RJ. Imaging strategy for detecting lung
metastases at presentation in patients with soft
tissue sarcomas. Eur J Cancer.
2008;44(13):1841–5.
7. Fong Y, Coit DG, Woodruff JM, Brennan MF.
Lymph node metastasis from soft tissue sarcoma
in adults. Analysis of data from a prospective
database of 1772 sarcoma patients. Ann Surg.
1993;217(1):72.
8. Edge SB, Byrd DR, Compton CC, et al. AJCC
(American Joint Committee on Cancer). Cancer
staging manual. 7th ed. New York: Springer;
2010, p 291.
9. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic
factors for patients with localized soft-tissue
sarcoma treated with conservation surgery and
radiation therapy: an analysis of 1225 patients.
Cancer. 2003;97(10):2530.
10. Gustafson P, Dreinhofer KE, Rydholm A. Soft
tissue sarcoma should be treated at a tumor
82 Rare Cancers Ther (2015) 3:69–87
center. A comparaison of quality of surgery in 375
patients. Acta Orthop Scand. 1994;65(1):47.
11. Trovik CS, Bauer HC, Alvegrad TA, et al. Surgical
margins, local recurrence and metastasis in soft
tissue sarcomas: 559 surgically-treated patients
from the Scandinavian Sarcoma Group Register.
Eur J Cancer. 2000;36(6):710–6.
12. Stoeckle E, Coindre JM, Kantor G, et al. Quality of
surgery in soft tissue sarcoma: a single centre
experience with the French Sarcoma Group (FSG)
surgical system. Cancer therapy. 2005;3:31–40.
13. National Comprehensive Cancer Network. Soft
tissue sarcoma (Version 1. 2015). http://www.
nccn.org/professionals/physician_gls/pdf/sarcoma.
pdf. Accessed 15 May 2015
14. Rosenberg SA, Tepper J, Glastein E, et al. The
treatment of soft tissue sarcomas of the
extremities: prospective randomized evaluations
of (1) limb-sparing surgery plus radiation therapy
compared with amputation and (2) the role of
adjuvant chemotherapy. Ann Surg. 1982;196(3):
305–15.
15. Rosenberg SA, Tepper J, Glatskin E, et al.
Prospective randomized evaluation of adjuvant
radiotherapy in adults with soft tissue sarcomas of
the extremities. Cancer. 1983;52:424–34.
16. Keus RB, Rutgers EJ, Ho GH, Gortzak E,
Albus-lutter CE, Hart AA. Limb-sparing therapy
of extremity soft tissue sarcomas: treatment
outcome and long term functional results. Eur J
Cancer. 1994;30A(10):1459–63.
17. Delaney TF, Harmon DC, Gebhardt MC. Local
treatment for primary soft tissue sarcoma of the
extremities and chest wall. In: Post TW, editor. Up
ToDate. Up ToDate: Waltham, MA; 2015.
18. Maduekwe UN, Hornicek FJ, Springfield DS, et al.
Role of sentinel lymph node biopsy in the staging
of synovial, epitheloid, and clear cell sarcomas.
Ann Surg. 2009;15(5):1356.
19. Andreou D, Boltdt H, Werner M, Hamann C, Pink
D, Tunn PU. Sentinel node biopsy in soft tissue
sarcoma subtypes with high propensity for
regional lymphatic spread–results of a large
prospective trial. Ann Oncol. 2013;25(5):1400–5.
20. Baldini EH, Gildgerg J, Jenner C, et al. Long term
outcomes after function-sparing surgery without
radiotherapy for soft tissue sarcoma of the
extremities and trunk. J Clin Oncol. 1999;17(10):
3252.
21. Pisters PW, Pollock RE, Lewis VO, et al. Long-term
results of prospective trial of surgery alone with
selective use of radiation for patients with T1
extremity and trunk soft tissue sarcomas. Ann
Surg. 2007;246(4):675.
22. Cahlon O, Brennan MF, Jia X, Qin LX, Singer S,
Atektiar KM. A prospective nomogram for local
recurrence risk in extremity soft tissue sarcomas
after limb-sparing surgery without adjuvant
radiation. Ann Surg. 2012;255(2):343.
23. Yang JC, Chang AE, Baker AR, et al. Randomized
prospective study of the benefit of adjuvant
radiation therapy in the treatment of soft tissue
sarcomas of the extremity. J Clin Oncol.
1998;16(1):197.
24. Pisters PW, Harisson LB, Leung DH, Woodruff JM,
Casper ES, Bernnan MF. Long-term results of
prospective randomized trial of adjuvant
brachytherapy in soft tissue sarcoma. J Clin
Oncol. 1996;14(3):859.
25. Pisters PW, Leung DH,Woodruff J, Shi W, Brennan
MF. Analysis of prognostic factors in 1041 patients
with localized soft tissue sarcomas of the
extremities. J Clin Oncol. 1996;14(5):1679–89.
26. Trovik CS, Bauer HC, Alvega˚rd TA, et al. Surgical
margins, local recurrence and metastasis in soft
tissue sarcomas: 559 surgically-treated patients
from the Scandinavian Sarcoma Group Register.
Eur J Cancer. 2000;36(6):710–6.
27. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel
SR, Benjamin RS. Surgical margins and reresection
in the management of patients with soft tissue
sarcoma using conservative surgery and radiation
therapy. Cancer. 2003;97(10):2544–53.
28. Khanfir K, Alzieu L, Terrier P, et al. Does adjuvant
radiation therapy increase loco-regional control
after optimal resection of soft-tissue sarcoma of
the extremities. Eur J Cancer. 2003;39(13):1872–
80.
29. Coindre JM, Terrier P, Bui NB, et al. Prognostic
factors in adult patients with locally controlled
soft tissue sarcoma. A study of 546 patients
from the French Federation of Cancer Centers
Sarcoma Group. J Clin Oncol.
1996;14(3):869–77.
30. O’Sullivan B, Davis AM, Turcotte R, et al.
Preoperative versus postoperative radiotherapy in
soft-tissue sarcoma of the limbs: a randomised
trial. Lancet. 2002;359(9325):2235.
31. O’Sullivan B, Davis AM, Turcotte R, et al. Five-year
results of a randomized phase III trial of
pre-operative versus postoperative radiotherapy
in extremity soft tissue sarcoma. J Clin Oncol.
2004;22(14 suppl):9007.
Rare Cancers Ther (2015) 3:69–87 83
32. O’Sullivan B, Griffin AM, Dickie CI, et al. Phase 2
study of preoperative image-guided
intensity-modulated radiation therapy to reduce
wound and combined modality morbidities in
lower extremity soft tissue sarcoma. Cancer.
2013;119(10):1878–84.
33. Lindberg RD, Martin RG, Romsdahl MM, Barkley
HT Jr. Conservative surgery and postoperative
radiotherapy in 300 adults with soft-tissue
sarcomas. Cancer. 1981;47(10):2391.
34. Sarcoma Meta-analysis Collaboration. Adjuvant
chemotherapy for localised resectable soft-tissue
sarcoma of adults: meta-analysis of individual
data. Lancet. 1997;350(9092):1647–54.
35. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R,
Figueredo A, Ghert M. A systematic meta-analysis
of randomized controlled trials of adjuvant
chemotherapy for localized resectable soft-tissue
sarcoma. Cancer. 2008;113(3):573–81.
36. Woll PJ, Reichardt P, Le Cesne A, et al. EORTC Soft
Tissue and Bone Sarcoma Group and the NCIC
Clinical Trials Group. Adjuvant chemotherapy
with doxorubicin, ifosfamide, and lenograstim
for resected soft-tissue sarcoma (EORTC 62931): a
multicentre randomised controlled trial. Lancet
Oncol. 2012;13(10):1045–54.
37. Le Cesne A, Ouali M, Leahy MG, et al.
Doxorubicin-based adjuvant chemotherapy in
soft tissue sarcoma: pooled analysis of two
STBSG-EORTC phase III clinical trials. Ann
Oncol. 2014;25(12):2425–32.
38. Jones RL, Fisher C, Al-Muderis O, Judson IR.
Differential sensitivity of liposarcoma subtypes to
chemotherapy. Eur J Cancer. 2005;41(18):2853.
39. Rosen G, Forscher C, Lowenbraun S, et al. Synovial
sarcoma. Uniform response of metastases to high
dose ifosfamide. Cancer. 1994;73(10):2506.
40. Ferrari A, Gronchi A, Casanova M, et al. Synovial
sarcoma: a retrospective analysis of 271 patients of
all ages treated at single institution. Cancer.
2004;101(3):627.
41. Eilber FC, Eilber FR, Eckardt J, et al. The impact of
chemotherapy on the survival of patients with
high grade primary extremity liposarcoma. Ann
Surg. 2004;240(4):686.
42. Angele MK, Albertsmeier M, Prix NJ, et al.
Effectiveness of regional hyperthermia with
chemotherapy for high-risk retroperitoneal and
abdominal soft-tissue sarcoma after complete
surgical resection: a subgroup analysis of a
randomized phase-III multicenter study. Ann
Surg. 2014;260(5):749–54.
43. Issel RD, Lindner LH, Verweij J, et al. Neo-adjuvant
chemotherapy alone or with regional
hyperthermia for localized high risk soft tissue
sarcoma: a randomised phase 3 multicentre study.
Lancet Oncol. 2010;11(6):561–70.
44. Gutman M, Inbar M, Lev-Shulsh D, et al. High
dose tumor necrosis factor-alpha and melphalan
administered via isolated limb perfusion for
advanced limb soft tissue sarcoma result in a
[90% response and limb preservation. Cancer.
1997;79(6):1129.
45. Eggermont AM, Schraffordt Koops H, Lie´nard D,
et al. Isolated limb perfusion with high-dose
tumor necrosis factor-alpha in combination with
interferon-gamma and melphalan for
nonresectabe extremity soft tissue sarcomas: a
multicenter trial. J Clin Oncol. 1996;14(10):2653.
46. Noorda EM, Vrouenraets BC, Nieweg OE, van
Coevorden F, van Slooten GW, Kroon BB.
Isolated limb perfusion with tumor necrosis
factor-alpha and melphalan for patients with
unresctable soft tissue sarcoma of the extremities.
Cancer. 2003;98(7):1483.
47. Grunhagen DJ, de Wilt JH, Graveland WJ,
Verhoef C, van Geel AN, Eggermont AM.
Outcome and prognostic factor analysis of 217
consecutive isolated limb perfusions with tumor
necrosis factor-alpha and melphalan for
limb-threatening soft tissue sarcoma. Cancer.
2006;106(8):1776.
48. Eggermont AM, Schraffordt Koops H, Klausner
JM, et al. Isolated limb perfusion with tumor
necrosis factor and melphalan for limb salvage
in 186 patients with locally advanced soft tissue
extremity sarcomas. The cumulative
multicenter European experience. Ann Surg.
1996;224(6):756.
49. Issels RD, Abdel-Rahman S, Wendtner C, et al.
Neoadjuvant combined with regional hypertermia
for locally advanced primary or recurrent high risk
adult soft tissue sarcomas of adults: long term
results of phase II study. Eur J Cancer.
2001;37(13):1599.
50. Pister PW, Patel SR, Prieto VG, et al. Phase I trial of
preoperative doxorubicin based concurrent
chemoradiation and surgical resection for
localized extremity and body wall soft tissue
sarcomas. J Clin Oncol. 2004;22(16):3375.
51. Toma S, Canavese G, Grimaldi A, et al.
Concomitant chemo-radiotherapy in the
treatment of locally advanced and/or metastatic
soft tissue sarcomas: experience of the National
Cancer Institute of Genoa. Oncol Rep. 2003;10(3):
641.
84 Rare Cancers Ther (2015) 3:69–87
52. Cormier JN, Patel SR, Herzog CE, et al. Concurrent
ifisfamide-based chemotherapy and irradiation.
Analysis of treatment related toxicity in 43
patients with sarcoma. Cancer. 2001;92(6):1550.
53. Kraybill WG, Harris J, Spiro IJ, et al. Phase II study
of neoadjuvant chemotherapy and radiation
therapy in the management of high risk, high
grade, soft tissue sarcomas of the extremities and
body wall. J Clin Oncol. 2006;24(4):619.
54. Gortzak E, Azzarelli A, Buesa J, et al. A randomized
phase II study on neo-adjuvant chemotherapy for
high-risk adult soft tissue sarcoma. Eur J Cancer.
2001;37:1096–103.
55. Antman K, Crowley J, Blacerzak SP, et al. An
intergroup phase III randomized study of
doxorubicin and dacarbazine with or without
ifosfamide and mesna in advanced soft tissue
sarcomas. J Clin Oncol. 1993;11(7):1276.
56. Elias A, Ryan L, Sulkes A, Collins J, Aisner J,
Antman KH. Response to mesna, doxorubicin,
ifosfamide, and dacarbazine in 108 patients with
metastatic or unresectable sarcoma and no prior
chemotherapy. J Clin Oncol. 1989;7(9):1208.
57. Driscoll DL. Treatment and local control of
primary extremity soft tissue sarcomas. J Surg
Oncol. 1999;71(3):155.
58. Zagars GK, Ballo MT, Piester PW, Pollock RE, Patel
SR, Benjamin RS. Prognostic factors for
diseases-specific survival after first relapse of soft
tissue sarcomas: analysis of 402 patients with
disease relapse after initial conservative surgery
and radiotherapy. Int J Radiat Oncol Biol Phys.
2003;57(3):739.
59. Levay J, O’Sullivan B, Catton C, et al. Outcome
and prognostic factors in soft tissue sacoma in the
adult. Int J Radiat Oncol Biol Phys. 1993;27(5):
1091.
60. Indelicato DJ, Meadows K, Gibbs CP Jr, Morris CG,
Scarborough MT, Zlotecki RA. Effectiveness and
morbidity associated with reirradiation in
conservative salvage management of recurrent
soft-tissue sarcoma. Int J Radiat Oncol Biol Phys.
2009;73(1):267.
61. Pearlstone DB, Janjan NA, Feig BW, et al.
Re-resection with brachytherapy for locally
recurrent soft tissue sarcoma arising in a
previously radiated field. Cancer J Sci Am.
1999;5(1):26.
62. Lans TE, Gru¨nhagen DJ, de Wilt JH, Van Geel AN,
Eggermont AM. Isolated limb perfusions with
tumor necrosis factor and melphalan for locally
recurrent soft tissue sarcoma in previously
irradiated limbs. Ann Surg Oncol. 2005;12(5):406.
63. Italiano A, Mathoulin-Pelissier S, Le Cesne A, et al.
Trends in survival for patients with metastatic
soft-tissue sarcoma. Cancer. 2011;117:1049–54.
64. Judson I, Verweij J, Gelderblom H, et al.
Doxorubicin alone versus intensified doxorubicin
plus ifosfamide for first-line treatment of advanced
or metastatisoft-tissue sarcoma: a randomised
controlled phase 3 trial. Lancet Oncol. 2014;15:
415–23.
65. Blay JY, Van Glabbeke M, Verweij J, et al.
Advanced soft-tissue sarcoma: a disease that is
potentially curable for a subset of patients treated
with chemotherapy. Eur J Cancer. 2003;39:64–9.
66. Blackmon SH, Shah N, Roth JA, et al. Resection of
pulmonary and extrapulmonary sarcomatous
metastases is associated with long-term survival.
Ann Thorac Surg. 2009;88(3):877–84.
67. Billingsley KG, Burt ME, Jara E, et al. Pulmonary
metatases from soft tissue sarcoma: analysis of
patterns of disease and postmetastases survival.
Ann Surg. 1999;229(5):602.
68. Bramwell VH, Anderson D, Charette ML.
Doxorubicin-based chemotherapy for the
palliative treatment of adult patients with locally
advanced or metastatic soft-tissue sarcoma: a
meta-analysis and clinical practice guideline.
Sarcoma. 2000;4:103–12.
69. Judson I, Radford JA, Harris M, et al. Randomised
phase II trial of pegylated liposomal doxorubicin
(DOXIL/CAELYX) versus doxorubicin in the
treatment of advanced or metastatic soft tissue
sarcoma: a study by the EORTC Soft Tissue and
Bone Sarcoma Group. Eur J Cancer. 2001;37:
870–7.
70. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer
S. The pharmacologic basis of ifosfamide use in
adult patients with advanced soft tissue sarcomas.
Oncologist. 2007;12:1351–60.
71. Van Oosterom AT, Mouridsen HT, Nielsen OS,
et al. Results of randomised studies of the EORTC
Soft Tissue and Bone Sarcoma Group (STBSG) with
two different ifosfamide regimens in first- and
second-line chemotherapy in advanced soft tissue
sarcoma patients. Eur J Cancer. 2002;38:2397–406.
72. Patel S, Vadhan-Raj S, Papadopolous N, et al.
High-dose ifosfamide in bone and soft tissue
sarcomas: results of phase II and pilot
studies-dose response and schedule dependence.
J Clin Oncol. 1997;15:2378–84.
Rare Cancers Ther (2015) 3:69–87 85
73. Sleijfer S, Ouali M, van Glabbeke M, et al.
Prognostic and predictive factors for outcome to
first-line ifosfamide-containing chemotherapy for
adult patients with advanced soft tissue sarcomas:
an exploratory, retrospective analysis on large
series from the European Organization for
Research. Eur J Cancer. 2010;46(1):72–83.
74. Rosen G, Forscher C, Lowenbraun S, et al. Synovial
sarcoma, Uniform response of metastases to high
dose ifosfamide. Cancer. 1994;73(10):2506–11.
75. Lorigan PL, Verweij J, Papai Z, et al. Phase III trial
of two investigational schedules of ifosfamide
compared with standard-dose doxorubicin in
advanced or metastatic soft tissue sarcoma: a
European Organisation for Research and
Treatment of Cancer Soft Tissue and Bone
Sarcoma Group Study. J Clin Oncol. 2007;25(21):
3144–50.
76. Le Cesne A, Antoine E, Spielmann M, et al.
High-dose ifosfamide: circumvention of resistance
to standard-dose ifosfamide in advanced soft tissue
sarcomas. J Clin Oncol. 1995;13:1600–8.
77. Martin-Liberal J, Alam S, Constantinidou A, et al.
Clinical activity and tolerability of a 14-day
infusional Ifosfamide schedule in soft-tissue
sarcoma. Sarcoma. 2013;868–973.
78. Gottlieb JA, Benjamin RS, Baker LH, et al. Role of
DTIC (NSC-45388) in the chemotherapy of
sarcomas. Cancer Treat Rep. 1976;60(2):199.
79. Zucali PA, Bertuzzi A, Parra HJ, Campagnoli E,
Qualiuolo V, Santoro A. The ‘‘old drug’’
dacarbazine as second/third line chemotherapy
in advanced soft tissue sarcomas. Invest New
Drugs. 2008;26(2):175.
80. Garcia del Muro X, Lopez-Pousa A, Martin J, et al.
A phase II trial of temozolomide as a 6-week,
continuous, oral schedule in patients with
advanced soft tissue sarcoma: a study by the
Spanish Group for Research on Sarcomas. Cancer.
2005;104(8):1706.
81. Penel N, Bui BN, Bay JO, et al. Phase II trial of
weekly paclitaxel for unresectable angiosarcoma:
the ANGIOTAX Study. J Clin Oncol.
2008;26:5269–74.
82. Pautier P, Floquet A, Penel N, et al. Randomized
multicenter and stratified phase II of gemcitabine
alone versus gemcitabine and docetaxel in
patients with metastatic or relapsed
leiomyosarcomas: a Federation Nationale des
Centres de Lutte Contre le Cancer French
Sarcoma Group Study (TAXOGEM). Oncologist.
2012;17(9):1213–20.
83. Maki RG, Wathen JK, Patel SR, et al. Randomized
phase II study of gemcitabine and docetaxel
compared with gemcitabine alone in patients with
metastatic soft tissue sarcomas: results of sarcoma
alliance for research through collaboration study
002. J Clin Oncol. 2007;25(19):2755.
84. Bramwell V, Blackstein M, Belanger K, et al. A
phase II study of docetaxel in chemotherapy-naı¨ve
patients with recurrent or metastatic adult soft
tissue sarcoma. Sarcoma. 1998;2:29–33.
85. Goldstein D, Cheuvart B, Trump DL, et al. Phase II
trial of carboplatin in soft tissue sarcoma. Am J
Clin Oncol. 1990;13(5):420.
86. Schlemmer M, Reichardt P, Verweij J, et al.
Paclitaxel in patients with advanced,
angiosarcomas of soft tissue: a retrospective study
of the EORTC soft tissue and bone sarcoma group.
Eur J Cancer. 2008;44:2433–6.
87. Hartmann JT, Oechsle K, Huober J, et al. An open
label, non-comparative phase II study of
gemcitabine as salvage treatment for patients
with pretreated adult type soft tissue sarcoma.
Invest New Drugs. 2006;24:249–53.
88. Von Burton G, Rankin C, Zalupski MM, et al. Phase
II trial of gemcitabine as first line chemotherapy in
patients with metastatic or unresectable soft tissue
sarcoma. Am J Clin Oncol. 2006;29:59–61.
89. Stacchiotti S, Palassini E, Sanfilippo R, et al.
Gemcitabine in advanced angiosarcoma: a
retrospective case series analysis from the Italian
Rare Cancer Network. Ann Oncol. 2012;23:501–8.
90. Schoffski P, et al. Activity of eribulin mesylate in
patients with soft-tissue sarcoma: a phase 2 study
in four independent histological subtypes. Lancet
Oncol. 2011;12:1045–52.
91. Scho¨ffski P, Maki RG, Italiano A, et al.
Randomized, open-label, multicenter, phase III
study of eribulin versus dacarbazine in patients
with leiomyosarcoma and adipocytic sarcoma.
J Clin Oncol. 2015;33(18 suppl):LBA10502.
92. Le Cesne A, et al. A retrospective pooled analysis of
trabectedin safety in 1132 patients with solid
tumors treated in phase II clinical trials. Investig
New Drugs. 2012;30:1193–202.
93. Demetri GD, Chawla SP, Von Mehren M, et al.
Efficacy and safety of trabectedin in patients with
advanced or metastatic liposarcoma or
leiomyosarcoma after failure of prior
anthracyclines and ifosfamide: results of a
randomized phase II study of two different
schedules. J Clin Oncol. 2009;27:4188–96.
86 Rare Cancers Ther (2015) 3:69–87
94. Demetri GD, Mehren VM, Jones RL, et al. A
randomized phase III study of trabectidin or
dacarbazin for the treatment of patients with
advanced liposarcoma or leiomyosarcoma. J Clin
Oncol. 2015;33(suppl):10503.
95. Antman K, Crowley J, Balcerzak SP. Randomized
comparison of doxorubicin and dacarbazine with
or without ifosfamide and mesna in advanced soft
tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75.
96. Borden EC, Amato DA, Rosenbaum C, et al.
Randomized comparison of three adriamycin
regimens for metastatic soft tissue sarcomas.
J Clin Oncol. 1987;5:840–50.
97. Seddon BM, Whelan J, Strauss SJ, et al. GeDDis: a
prospective randomized controlled phase III trial
of gemcitabine and docetaxel compared with
doxorubicin as first-line treatment in previously
untreated advanced or metastatic soft tissue
sarcomas (EudraCT 2009-014907-29). J Clin
Oncol. 2015;33(suppl):10500.
98. Garcı´a-Del-Muro X, Lo´pez-Pousa A, Maurel J, et al.
Randomized phase II study comparing
gemcitabine plus dacarbazine versus dacarbazine
alone in patients with previously treated soft tissue
sarcoma: a Spanish Group for Research on
Sarcomas study. J Clin Oncol. 2011;29:2528–33.
99. Kasper B, Sleijfer S, Litie`re S, et al. Long-term
responders and survivors on pazopanib for
advanced soft tissue sarcomas: subanalysis of two
European Organization for Research and
Treatment of Cancer (EORTC) clinical trials
62043 and 62072. Ann Oncol. 2014;25:719–24.
100. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib,
a multikinase angiogenesis inhibitor, in patients
with relapsed or refractory advanced soft tissue
sarcoma: a phase II study from the European
Organisation for Research and Treatment of
Cancer-Soft Tissue and Bone Sarcoma Group
(EORTC) Study 620. J Clin Oncol. 2009;27.
101. van der Graaf WT, Blay JY, Chawla SP, et al.
EORTC Soft Tissue and Bone Sarcoma Group;
PALETTE study group. Pazopanib for metastatic
soft-tissue sarcoma (PALETTE): a randomised,
double-blind, placebocontrolled phase 3 trial.
Lancet. 2012;379:1879–86.
102. Endo M, Nielsen TO. Pazopanib for metastatic
soft-tissue sarcoma. Lancet. 2012;380(9844):801
(author reply 801).
103. Kasper B, Sleijfer S, Litie`re S, et al. Long-term
responders and survivors on pazopanib for
advanced soft tissue sarcomas: subanalysis of two
European Organisation for Research and
Treatment of Cancer (EORTC) clinical trials
62043 and 62072. Ann Oncol. 2014;25:719–24.
104. Kummar S, Allen D, Monks A, et al. Cediranib for
metastatic alveolar soft part sarcoma. J Clin Oncol.
2013;31(18):2296–302.
105. Stacchiotti S, Negri T, Palassini E, et al. Sunitinib
malate and figitumumab in solitary fibrous tumor:
patterns and molecular bases of tumor response.
Mol Cancer Ther. 2010;9(5):1286–97.
106. Stacchiotti S, Tamborini E, Marrari A, et al.
Response to sunitinib malate in advanced
alveolar soft part sarcoma. Clin Cancer Res.
2009;15:1096–104.
107. Butrynski JE, D’Adamo DR, Hornick JL, et al.
Crizotinib in ALK-rearranged inflammatory
myofibroblastic tumor. N Engl J Med.
2010;363(18):1727–33.
108. Mir O, Brodowicz T, Wallet J, et al. Activity of
regorafenib in leimyosarcomas and other types of
soft tissue sarcomas: results of double- blind,
randomized placebo controlled phase II trial.
J Clin Oncol. 2015;33(suppl):10504.
109. Wagner AJ, Malinowska-Kolodziej I, Morgan JA,
et al. Clinical activity of mTOR inhibition with
sirolimus in malignant perivascular epithelioid
cell tumors: targeting the pathogenic activation
of mTORC1 in tumors. J Clin Oncol. 2010;28(5):
835–40.
110. Tap WD, Jones RL, Chmielowski B, et al. A
randomized phase Ib/II study evaluating safety
and efficacy of olaratumab (IMC-303) a human
anti.platelet derived growth factor a (PDGFRa)
monoclonal antibody with or without
doxorubicin in advanced STS. J Clin Oncol.
2015;33(suppl):10501.
Rare Cancers Ther (2015) 3:69–87 87
